AP
AGRX

AlpInvest Partners’s Agile Therapeutics AGRX Stock Holding History

AlpInvest Partners’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-14
Closed -$158K – 21
2016
Q4 		$158K Hold
14
– – 0.56% 14
2016
Q3 		$193K Hold
14
– – 0.48% 14
2016
Q2 		$211K Buy
+14
New +$192K 0.42% 24

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

AlpInvest Partners's AGRX Position: Q1 2017 in Review

AlpInvest Partners sold out of Agile Therapeutics (AGRX) in Q1 2017, closing a stake of 14 shares — an estimated $158K sold.

AlpInvest Partners first reported a position in AGRX in Q2 2016 and held it in 3 quarters. The position peaked at $211K in Q2 2016. 48 funds tracked by Wall St. Rank hold AGRX as of Q1 2017.

  • AlpInvest Partners reported no remaining Agile Therapeutics position as of Q1 2017 after selling out during the quarter.
  • AlpInvest Partners sold 14 Agile Therapeutics shares in Q1 2017, an estimated $158K.
  • AlpInvest Partners first reported a position in Agile Therapeutics in Q2 2016 and held it in 3 quarters.
  • AlpInvest Partners's Agile Therapeutics position peaked at $211K in Q2 2016.
  • 48 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2017.

Based on AlpInvest Partners's 13F filing for Q1 2017, filed 11 May 2017.